Organigram Holdings Midday Review: BAT Partnership and EU Medical Exports Drive Q3 FY2026 Outperformance
TL;DR: Organigram Holdings (OGI) delivered strong Q3 FY2026 results, with net revenue of approximately C$52.3 million representing a 9% year-over-year gain, driven primarily by accelerating international medical cannabis exports to Germany and the United Kingdom. The British American Tobacco-backed Canadian LP continues to differentiate itself through its Centre of Excellence R&D program and export-first strategy […]
Green Thumb Industries Q2 2026 Earnings Preview: Free Cash Flow and 280E Savings in Focus
TL;DR: Green Thumb Industries (GTBIF) is set to report Q2 2026 results in late July, and analysts are watching three key metrics: free cash flow generation, the early financial impact of 280E relief from April’s medical rescheduling, and same-store sales trends across its 98 retail locations. With MSOS at 2026 highs and rescheduling hearings underway, […]
Cannabis Stocks Friday Morning: MSOS Extends 2026 Highs as Rescheduling Hearings Enter Day 2
TL;DR: Cannabis equities are maintaining elevated positions Friday morning as the Department of Justice adult-use rescheduling hearings enter a second day in Washington. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed 48.5% since the end of Q1, outpacing broader equity benchmarks, with multi-state operators leading the advance. Investors are watching the hearing proceedings closely, […]
280E in Two Acts: How April Medical Rescheduling Changed MSO Taxes and What Adult-Use Hearings Would Complete
TL;DR: The April 23 rescheduling of medical cannabis to Schedule III delivered the first real relief from Section 280E in the federal tax code’s three-decade grip on the cannabis industry. But for the largest multi-state operators — whose revenues are overwhelmingly adult-use — the more consequential change awaits the outcome of the ongoing DOJ adult-use […]
MSOS Sector Positions for a Pivotal Friday as DOJ Rescheduling Hearings Begin — Outlook for June 26
TL;DR: Thursday, June 25 delivered a trifecta of structural catalysts for the cannabis sector — DOJ rescheduling hearings formally opened, Tilray posted record international revenue, and Curaleaf cleared a major uplisting hurdle. With the MSOS sector holding near 2026 highs heading into Friday’s session, investors are now watching for hearing testimony and follow-through volume to […]
Tilray Brands Posts Record Q3 FY2026 Revenue as International Cannabis Surges 73%
TL;DR: Tilray Brands (Nasdaq: TLRY) reported record fiscal third-quarter revenue of $206.7 million for the period ending February 28, 2026, up 11% year-over-year, driven by a 73% surge in international cannabis revenue and steady gains across its Canadian and wellness segments. The company posted its first meaningful adjusted net income and reaffirmed full-year fiscal 2026 […]
DOJ Begins Adult-Use Cannabis Rescheduling Hearings — Full 280E Relief Now on the Table
TL;DR: The U.S. Department of Justice has opened formal hearings in late June 2026 to evaluate rescheduling adult-use cannabis from Schedule I, following the landmark April 23 move of medical cannabis to Schedule III. A successful outcome would eliminate 280E taxation entirely for multi-state operators (MSOs), potentially unlocking hundreds of millions in annual cash flow […]
Curaleaf Shareholders Approve Delaware Redomicile, Clearing a Key Hurdle Toward U.S. Exchange Uplisting
TL;DR: Curaleaf Holdings shareholders voted on June 22 to approve the company’s continuation as a Delaware corporation, a structural step that repositions the largest U.S. cannabis multi-state operator for a potential listing on a major American stock exchange. The Delaware redomicile follows months of preparation for an eventual Nasdaq or NYSE uplisting, a move that […]
DEA Judge Finalizes Cannabis Rescheduling Hearing Timeline as MSOS Sector Holds 2026 Highs
TL;DR: A Drug Enforcement Administration administrative law judge formally set the hearing schedule for cannabis rescheduling proceedings today, June 25, signaling that the multi-year regulatory odyssey toward Schedule III classification is entering its most decisive phase. The DEA judge declined to expand the participant list, narrowing the adversarial process to already-qualified parties. Cannabis equities, as […]
Cultivation Consolidation Wave: Which Operators Win?
By Sheeba M. | June 16, 2026 Consolidation Wave: Which Operators Win? TL;DR: Oversupply forces consolidation; winners have efficient cultivation tech and scale. The cannabis cultivation market enters consolidation. Mid-sized growers struggle against operators investing in automation. Megaproducers have scale advantages; craft operators have premium positioning. Reports from Curaleaf and Trulieve show critical metrics. Leaders […]